| Fiscal Period | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Period End Date | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
| Total Liabilities Shareholders' Equity | 8,232.72 | 7,806.16 | 6,672.53 | 6,063.47 |
| Accumulated Depreciation Total | -1,533.89 | -1,307.58 | -1,104.69 | -931.58 |
| Cash Equivalents | 28.12 | 60.61 | 0.08 | 0.07 |
| Other Liabilities Total | 355.61 | 354.17 | 105.47 | 113.32 |
| Accrued Expenses | 199.48 | 193.07 | 173.69 | 155.79 |
| Long Term Debt | 187.34 | 761.92 | 737.18 | 707.76 |
| Common Stock Total | 189.48 | 181.15 | 180.85 | 180.85 |
| Other Equity Total | 82.86 | 48.73 | 26.50 | 15.67 |
| Other Current Assets Total | 5.94 | 9.65 | 7.46 | 7.65 |
| Prepaid Expenses | 89.31 | 94.44 | 96.17 | 142.90 |
| Total Assets | 8,232.72 | 7,806.16 | 6,672.53 | 6,063.47 |
| Current Portof LT Debt/ Capital Leases | 100.87 | 390.66 | 329.66 | 297.68 |
| Additional Paid- In Capital | 785.25 | 9.88 | - | - |
| Cash | 127.41 | 108.40 | 242.27 | 162.78 |
| Total Equity | 4,446.19 | 2,952.28 | 2,501.13 | 1,987.55 |
| Long Term Investments | 22.13 | 19.99 | 58.15 | 46.13 |
| Retained Earnings( Accumulated Deficit) | 3,388.59 | 2,712.52 | 2,293.77 | 1,791.03 |
| Total Common Shares Outstanding | 18.95 | 18.91 | 18.91 | 18.91 |
| Property/ Plant/ Equipment Total- Gross | 3,961.01 | 3,704.79 | 3,319.44 | 2,917.04 |
| Tangible Book Valueper Share Common Eq | 184.67 | 109.25 | 114.10 | 85.08 |
| Goodwill Net | 367.78 | 378.69 | 217.74 | 217.39 |
| Total Liabilities | 3,786.54 | 4,853.88 | 4,171.41 | 4,075.92 |
| Total Debt | 1,022.75 | 2,334.97 | 2,334.30 | 2,217.20 |
| Short Term Investments | 85.13 | 348.39 | 204.48 | 145.54 |
| Cashand Short Term Investments | 240.66 | 517.39 | 446.83 | 308.39 |
| Total Receivables Net | 2,288.13 | 2,113.34 | 1,902.43 | 1,515.74 |
| Notes Payable/ Short Term Debt | 474.62 | 961.98 | 1,145.33 | 1,090.96 |
| Deferred Income Tax | 120.03 | 137.42 | 38.89 | 42.61 |
| Accounts Receivable- Trade Net | 2,002.92 | 1,873.48 | 1,659.73 | 1,313.41 |
| Property/ Plant/ Equipment Total- Net | 2,427.12 | 2,397.21 | 2,214.76 | 1,985.46 |
| Minority Interest | 195.37 | 169.48 | 148.53 | 126.59 |
| Total Current Liabilities | 2,668.27 | 3,210.47 | 3,019.19 | 2,964.83 |
| Total Inventory | 1,931.81 | 1,525.10 | 1,383.03 | 1,449.42 |
| Accounts Payable | 1,479.58 | 1,309.37 | 1,086.11 | 1,125.19 |
| Other Currentliabilities Total | 413.72 | 355.41 | 284.41 | 295.21 |
| Total Long Term Debt | 447.25 | 982.34 | 859.31 | 828.56 |
| Intangibles Net | 579.23 | 507.77 | 125.81 | 161.36 |
| Other Long Term Assets Total | 156.52 | 138.07 | 136.76 | 143.80 |
| Note Receivable- Long Term | 124.08 | 104.53 | 83.41 | 85.23 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 4,555.86 | 4,259.92 | 3,835.91 | 3,424.10 |
| Capital Lease Obligations | 259.92 | 220.42 | 122.14 | 120.80 |
Emcure Pharmaceuticals Dividend Emcure Pharmaceuticals Bonus Emcure Pharmaceuticals News Emcure Pharmaceuticals AGM Emcure Pharmaceuticals Rights Emcure Pharmaceuticals Splits Emcure Pharmaceuticals Board Meetings Emcure Pharmaceuticals Key Metrics Emcure Pharmaceuticals Shareholdings Emcure Pharmaceuticals Profit Loss Emcure Pharmaceuticals Cashflow Emcure Pharmaceuticals Q1 Results Emcure Pharmaceuticals Q2 Results Emcure Pharmaceuticals Q3 Results Emcure Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks